SCHEMBL6728046

SCHEMBL6728046

Cc1cc(COc2cc(-c3ccc(N)cc3)nc(-c3ccccc3)n2)ccc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
HPGD P15428 2/20 0.46
KMT2A Q03164 2/20 0.46
LTB4R Q15722 3/20 0.44
RXRA P19793 1/20 0.43
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
GLA P06280 1/20 0.42
LDHA P00338 1/20 0.42
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
MAPK1 P28482 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
VCP P55072 2/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
AXL P30530 1/20 0.39
MERTK Q12866 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6728569 0.86 LTB4R (0.47) ALDH1A1MEN1MAPTHPGDKMT2A
SCHEMBL6728049 0.83 MEN1 (0.48) ALDH1A1MEN1MAPTHPGDKMT2A
SCHEMBL4804158 0.80 RXRA (0.53) MEN1HPGDKMT2ARXRAMAPK1
SCHEMBL4802532 0.76 CTRC (0.55) MEN1MAPTHPGDKMT2ALTB4R
SCHEMBL4807278 0.75 RXRA (0.48) HPGDRXRAKDM4EMAPK1NPC1
SCHEMBL8497207 0.71 RXRA (0.59) ALDH1A1MEN1MAPTKMT2ARXRA
SCHEMBL6728566 0.70 MAPT (0.52) ALDH1A1MEN1MAPTHPGDKMT2A
SCHEMBL8987052 0.69 LTB4R (0.59) LTB4RRXRAMCL1
SCHEMBL6733353 0.69 POLB (0.62) ALDH1A1MEN1MAPTKMT2AKDM4E
SCHEMBL2583060 0.68 MCL1 (0.52) MEN1KMT2AMRGPRX4MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110757-A1 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis ARRHENIUS THOMAS (US) 2004-06-10 US disclosed
EP-1370250-A2 FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP disclosed
WO-2002076438-A2 FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110757-A1 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis FLT1, FLT4, TEK ALDH1A1 757/4885MEN1 1965/4885MAPT 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.